Marea reports early Phase 2 data for cholesterol-lowering drug it licensed from Novartis

Marea Therapeutics on Friday posted some encouraging results with its lead program, a triglyceride-lowering medicine for cardiovascular disease, that could give an indication of whether the investors in its $190 million raise ...